Loading stock data…
$11.48+0.17 (+1.50%)
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States.
ORIC Pharmaceuticals, Inc. in the Healthcare sector is trading at $11.48 with a market capitalization of $1.3B. Wall Street consensus targets $21.43 (14 analysts), implying a +86.7% move over the next 12 months. The stock is currently 22% below its 52-week high of $14.68, remaining 4.6% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$45.30M↓ | -$39.62M↓ | -$34.55M↑ | -$36.67M↑ | -$39.06M |
| Net Income | -$41.49M↓ | -$35.77M↓ | -$30.50M↑ | -$32.59M↑ | -$36.35M |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozerti...